- Home
- GLPG vs VCEL Comparison
GLPG vs VCEL Comparison
Compare GLPG & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- VCEL
- Stock Information
- Founded
- GLPG 1999
- VCEL 1989
- Country
- GLPG Belgium
- VCEL United States
- Employees
- GLPG N/A
- VCEL N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLPG Health Care
- VCEL Health Care
- Exchange
- GLPG Nasdaq
- VCEL Nasdaq
- Market Cap
- GLPG 2.1B
- VCEL 1.8B
- IPO Year
- GLPG 2005
- VCEL 1997
- Fundamental
- Price
- GLPG $29.89
- VCEL $37.20
- Analyst Decision
- GLPG Hold
- VCEL Strong Buy
- Analyst Count
- GLPG 4
- VCEL 6
- Target Price
- GLPG $30.00
- VCEL $58.60
- AVG Volume (30 Days)
- GLPG 209.6K
- VCEL 638.8K
- Earning Date
- GLPG 11-05-2025
- VCEL 11-06-2025
- Dividend Yield
- GLPG N/A
- VCEL N/A
- EPS Growth
- GLPG N/A
- VCEL 2045.40
- EPS
- GLPG N/A
- VCEL 0.13
- Revenue
- GLPG $323,674,692.00
- VCEL $249,119,000.00
- Revenue This Year
- GLPG $1.77
- VCEL $18.35
- Revenue Next Year
- GLPG $0.44
- VCEL $22.26
- P/E Ratio
- GLPG N/A
- VCEL $277.87
- Revenue Growth
- GLPG 5.43
- VCEL 16.13
- 52 Week Low
- GLPG $22.36
- VCEL $29.24
- 52 Week High
- GLPG $37.78
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- GLPG 34.46
- VCEL 60.38
- Support Level
- GLPG $30.92
- VCEL $33.76
- Resistance Level
- GLPG $31.85
- VCEL $37.00
- Average True Range (ATR)
- GLPG 0.81
- VCEL 1.42
- MACD
- GLPG -0.27
- VCEL 0.11
- Stochastic Oscillator
- GLPG 1.70
- VCEL 98.28
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.